Skip to main content
. Author manuscript; available in PMC: 2023 Apr 9.
Published in final edited form as: Int Forum Allergy Rhinol. 2022 Jan 10;12(9):1148–1183. doi: 10.1002/alr.22953

Table V:

Summary of evidence for intranasal corticosteroid use in CF CRS

Study Year Study Design LOE Number
of
Subjects		 Study
Groups		 Intervention Primary Endpoint Conclusion
Donaldson36 1988 Retrospective cohort study 3 30 CF CRS Beclomethasone dipropionate: 2 puffs twice daily with subsequent adjustment

  1. Sinonasal symptoms

  2. Polyp size

 11/13 patients without polyps reported improvement in symptoms. 11/16 patients with polyps had symptoms, and all improved on medication. Of the 16 patients with polyps: 7 resolved, 3 regressed, 4 had no change, and 2 increased.
Costantini35 1990 Case series 4 14 CF CRS Beclomethasone dipropionate spray: 2-3x/day x 2 months

  1. Anterior rhinoscopy

  2. Rhinomanometry

 Significant reduction in nasal resistance after 2 months. 85.7% of patients demonstrated a “reduction or disappearance” of polyps.
Hadfield34 2000 RCT 2 46 CF CRS Betamethasone nasal drops: twice daily x 6 weeks versus placebo

  1. Sinonasal symptoms via visual analog scale

  2. Lund-Mackay endoscopic score

 22/46 patients completed trial, demonstrating a significant reduction in polyp size. No significant difference in sinonasal symptoms between groups.
Zemke37 2019 Prospective cohort study 3 33 CF CRS “Nasal steroids”

  1. SNOT-22

  2. Modified Lund-Kennedy CT score

 48.5% of the study population used INCS, which was associated with significantly lower SNOT-22 and modified Lund-Kennedy scores.

CF: cystic fibrosis; CRS: chronic rhinosinusitis; RCT: randomized control trial; SNOT-22: 22 item Sino-Nasal Outcome Test